African Swine Fever drug may soon be available to Chronic Fatigue Syndrome patients.
Dr. Robert Naviaux talking to Gita Gupta:
"We are hopeful that the new supplier of suramin will, in the long run, offer a simpler path forward and fewer potential delays in testing. If future clinical trials show that suramin is safe and effective in treating autism, then the FDA will have all the data they need to make a decision on approval in a shorter period of time than before. Ultimately, this means that the drug can become available for patients with autism or ME/CFS faster than was possible before."
https://tacanowblog.com/2018/03/08/suramin-autism-trial-update/
Is Naviaux really treating African Swine Fever in autism patients without realizing it?
http://naviauxlab.ucsd.edu/science-item/autism-research/
From the Naviaux Group:
"We think of autism as a neurometabolic and neuroimmune syndrome that is caused by the pathological persistence of the cell danger response (CDR). Both genes and environment can activate the CDR, which consists of about 30 metabolic pathways that work together to defend the cell against danger or stress3,5. When activated during early child development, the CDR can have a significant impact on behavior and brain development. The CDR is maintained by increased purinergic signaling6-8 that results from the release of nucleotides like ATP, ADP, UTP, UDP, and other metabolites that trace to mitochondria in cells under stress. Purinergic receptors are widely distributed on every cell type in the body. When activated, they can signal danger or trigger inflammation and pain. Nucleotides like ATP are co-neurotransmitters and neuromodulators at every synaptic junction studied to date. They are particularly important for cells in the nervous system, immune system, and the GI tract, which in turn, affects the gut microbiome. Suramin is a non-selective inhibitor of purinergic signaling, an antipurinergic drug, or APD for short. Suramin works in several ways to inhibit purinergic signaling. One way is to act as a competitive inhibitor of ATP binding to cell surface receptors. Another way is to block the release of intracellular ATP through pannexin-P2X7 channels into the extracellular space. Working in these ways, suramin sends an “all’s clear” signal to the cell. One way to think about suramin action is as “molecular armistice therapy”—a metabolic signal that the danger has passed and cellular resources can be directed away from defense and returned to “peace time” activities like normal neurodevelopment, healing, and growth."
Is this a complicated way of inadvertently saying that he is treating HHV-6 (which is suspected of really being African Swine Fever) with a drug that has show effectiveness against African Swine Fever?
Background on Suramin as a treatment of African Swine Fever (which may actually be HHV-6, HHV-7 and HHV-8 in humans)
Actinobolin, atropine, carrageenan, megalomycin C, suramin, and tetracenomycin C were tested for their activity against African swine fever virus replication. Both viral inhibitory potency and cytotoxicity were investigated. Megalomycin C, suramin, atropine, and carrageenan exhibited significant activity. Megalomycin C was the most active of the four agents with respect to the concentration of compound that blocked the formation of infectious virus by 50%. Suramin was the next most active agent in this respect, but because of its lower cytotoxicity, it had the most favorable therapeutic index.
Suramin is showing promise in the treatment of autism and may be tried for Chronic Fatigue Syndrome.
Is it because HHV-6 and related viruses are potential triggers of autism and CFS and the virus is allegedly a form of African Swine Fever that was renamed by Robert Gallo after he stole credit for the discovery of African Swine Fever in AIDS patients by John Beldekas and Jane Teas? (See Beldekas/Teas story here.)
This provocative book will end the injustice of the silent treatment Neenyah Ostrom's reporting has been getting from the media and The Chronic Fatigue Syndrome community. Ostrom blew the lid off one of the biggest medical secrets of our time: the link between the Chronic Fatigue Syndrome epidemic and AIDS.
Ostrom interviewed most of the major researchers in the field, as well as countless patients and government scientists. She uncovered so many similarities between Chronic Fatigue Syndrome and AIDS that she came to the conclusion that they are part of the same epidemic, and she argued that until their connection is admitted by top government researchers, there is little hope of making real progress in the fight against Chronic Fatigue Syndrome.
Charles Ortleb's book captures all the challenges and excitement of running a small newspaper that was publishing a brilliant journalist who essentially was the Woodward and Bernstein of the Chronic Fatigue Syndrome epidemic. In Rolling Stone, David Black said Ortleb's newspaper deserved a Pulitzer Prize.
"We are hopeful that the new supplier of suramin will, in the long run, offer a simpler path forward and fewer potential delays in testing. If future clinical trials show that suramin is safe and effective in treating autism, then the FDA will have all the data they need to make a decision on approval in a shorter period of time than before. Ultimately, this means that the drug can become available for patients with autism or ME/CFS faster than was possible before."
https://tacanowblog.com/2018/03/08/suramin-autism-trial-update/
Is Naviaux really treating African Swine Fever in autism patients without realizing it?
http://naviauxlab.ucsd.edu/science-item/autism-research/
From the Naviaux Group:
"We think of autism as a neurometabolic and neuroimmune syndrome that is caused by the pathological persistence of the cell danger response (CDR). Both genes and environment can activate the CDR, which consists of about 30 metabolic pathways that work together to defend the cell against danger or stress3,5. When activated during early child development, the CDR can have a significant impact on behavior and brain development. The CDR is maintained by increased purinergic signaling6-8 that results from the release of nucleotides like ATP, ADP, UTP, UDP, and other metabolites that trace to mitochondria in cells under stress. Purinergic receptors are widely distributed on every cell type in the body. When activated, they can signal danger or trigger inflammation and pain. Nucleotides like ATP are co-neurotransmitters and neuromodulators at every synaptic junction studied to date. They are particularly important for cells in the nervous system, immune system, and the GI tract, which in turn, affects the gut microbiome. Suramin is a non-selective inhibitor of purinergic signaling, an antipurinergic drug, or APD for short. Suramin works in several ways to inhibit purinergic signaling. One way is to act as a competitive inhibitor of ATP binding to cell surface receptors. Another way is to block the release of intracellular ATP through pannexin-P2X7 channels into the extracellular space. Working in these ways, suramin sends an “all’s clear” signal to the cell. One way to think about suramin action is as “molecular armistice therapy”—a metabolic signal that the danger has passed and cellular resources can be directed away from defense and returned to “peace time” activities like normal neurodevelopment, healing, and growth."
Is this a complicated way of inadvertently saying that he is treating HHV-6 (which is suspected of really being African Swine Fever) with a drug that has show effectiveness against African Swine Fever?
Background on Suramin as a treatment of African Swine Fever (which may actually be HHV-6, HHV-7 and HHV-8 in humans)
New agents active against African swine fever virus.
Abstract
Parent Personal Statements of Their Observations from Phase I/II Randomized Clinical Trial of Low-Dose Suramin in Autism Spectrum Disorder
The definitive history of the
Chronic Fatigue Syndrome cover-up.
As the publisher and editor-in-chief of a small newspaper in New York, Charles Ortleb was the first journalist to devote a publication to uncovering the truth about Chronic Fatigue Syndrome. He assigned Neenyah Ostrom the duty of following every twist and turn of the Chronic Fatigue Syndrome story. No newspaper in the world did more to warn the world about the virus called HHV-6 which seems to be triggering Chronic Fatigue Syndrome and many other immunological disorders.This provocative book will end the injustice of the silent treatment Neenyah Ostrom's reporting has been getting from the media and The Chronic Fatigue Syndrome community. Ostrom blew the lid off one of the biggest medical secrets of our time: the link between the Chronic Fatigue Syndrome epidemic and AIDS.
Ostrom interviewed most of the major researchers in the field, as well as countless patients and government scientists. She uncovered so many similarities between Chronic Fatigue Syndrome and AIDS that she came to the conclusion that they are part of the same epidemic, and she argued that until their connection is admitted by top government researchers, there is little hope of making real progress in the fight against Chronic Fatigue Syndrome.
Charles Ortleb's book captures all the challenges and excitement of running a small newspaper that was publishing a brilliant journalist who essentially was the Woodward and Bernstein of the Chronic Fatigue Syndrome epidemic. In Rolling Stone, David Black said Ortleb's newspaper deserved a Pulitzer Prize.
